Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Bill to Amend Infectious Disease Act and Other Laws Enter Diet Deliberations
Japan’s parliament started deliberations on a comprehensive bill to amend a series of health-related laws, including the Infectious Disease Act and the Medical Care Act, at a Lower House plenary session on October 25. The proposed amendment of the Infectious…
To read the full story
Related Article
- Japan Enacts Bill to Amend Infectious Disease Act
December 5, 2022
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- Bill to Amend Infectious Disease Act Clears Lower House
November 9, 2022
- Japan Cabinet OKs Bill to Amend Infectious Disease Act, Other Laws
October 11, 2022
- Japan Convenes Diet Session; Bill Submission Planned to Amend Infectious Disease Act, Medical Care Act
October 4, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…